vs

Side-by-side financial comparison of Rhinebeck Bancorp, Inc. (RBKB) and AVITA Medical, Inc. (RCEL). Click either name above to swap in a different company.

AVITA Medical, Inc. is the larger business by last-quarter revenue ($17.6M vs $13.5M, roughly 1.3× Rhinebeck Bancorp, Inc.). Rhinebeck Bancorp, Inc. runs the higher net margin — 17.3% vs -66.0%, a 83.3% gap on every dollar of revenue. On growth, Rhinebeck Bancorp, Inc. posted the faster year-over-year revenue change (1701.1% vs -4.3%). Rhinebeck Bancorp, Inc. produced more free cash flow last quarter ($10.9M vs $-6.1M). Over the past eight quarters, AVITA Medical, Inc.'s revenue compounded faster (26.0% CAGR vs 14.0%).

Rhinebeck Bancorp, Inc. is a US regional bank holding company based in New York. It operates Rhinebeck Bank, offering retail and commercial banking services including deposit accounts, loans, mortgages and wealth management, mainly serving consumers and small-to-medium businesses across New York's Hudson Valley region.

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East...

RBKB vs RCEL — Head-to-Head

Bigger by revenue
RCEL
RCEL
1.3× larger
RCEL
$17.6M
$13.5M
RBKB
Growing faster (revenue YoY)
RBKB
RBKB
+1705.4% gap
RBKB
1701.1%
-4.3%
RCEL
Higher net margin
RBKB
RBKB
83.3% more per $
RBKB
17.3%
-66.0%
RCEL
More free cash flow
RBKB
RBKB
$17.0M more FCF
RBKB
$10.9M
$-6.1M
RCEL
Faster 2-yr revenue CAGR
RCEL
RCEL
Annualised
RCEL
26.0%
14.0%
RBKB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RBKB
RBKB
RCEL
RCEL
Revenue
$13.5M
$17.6M
Net Profit
$2.3M
$-11.6M
Gross Margin
81.2%
Operating Margin
21.7%
-59.1%
Net Margin
17.3%
-66.0%
Revenue YoY
1701.1%
-4.3%
Net Profit YoY
188.0%
-0.3%
EPS (diluted)
$0.21
$-0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RBKB
RBKB
RCEL
RCEL
Q4 25
$13.5M
$17.6M
Q3 25
$14.0M
$17.1M
Q2 25
$13.1M
$18.4M
Q1 25
$12.8M
$18.5M
Q4 24
$750.0K
$18.4M
Q3 24
$773.0K
$19.5M
Q2 24
$10.7M
$15.2M
Q1 24
$10.4M
$11.1M
Net Profit
RBKB
RBKB
RCEL
RCEL
Q4 25
$2.3M
$-11.6M
Q3 25
$2.7M
$-13.2M
Q2 25
$2.7M
$-9.9M
Q1 25
$2.3M
$-13.9M
Q4 24
$-2.7M
$-11.6M
Q3 24
$-8.1M
$-16.2M
Q2 24
$975.0K
$-15.4M
Q1 24
$1.1M
$-18.7M
Gross Margin
RBKB
RBKB
RCEL
RCEL
Q4 25
81.2%
Q3 25
81.3%
Q2 25
81.2%
Q1 25
84.7%
Q4 24
87.6%
Q3 24
83.7%
Q2 24
86.1%
Q1 24
86.4%
Operating Margin
RBKB
RBKB
RCEL
RCEL
Q4 25
21.7%
-59.1%
Q3 25
23.9%
-53.6%
Q2 25
26.6%
-60.5%
Q1 25
22.9%
-63.9%
Q4 24
-444.9%
-54.1%
Q3 24
-1332.3%
-70.6%
Q2 24
11.8%
-102.8%
Q1 24
13.9%
-155.0%
Net Margin
RBKB
RBKB
RCEL
RCEL
Q4 25
17.3%
-66.0%
Q3 25
19.3%
-77.3%
Q2 25
20.8%
-53.9%
Q1 25
17.9%
-74.9%
Q4 24
-353.9%
-63.0%
Q3 24
-1042.9%
-82.9%
Q2 24
9.2%
-101.3%
Q1 24
10.8%
-168.0%
EPS (diluted)
RBKB
RBKB
RCEL
RCEL
Q4 25
$0.21
$-0.37
Q3 25
$0.25
$-0.46
Q2 25
$0.25
$-0.38
Q1 25
$0.21
$-0.53
Q4 24
$-0.24
$-0.44
Q3 24
$-0.75
$-0.62
Q2 24
$0.09
$-0.60
Q1 24
$0.10
$-0.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RBKB
RBKB
RCEL
RCEL
Cash + ST InvestmentsLiquidity on hand
$18.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$136.9M
$-16.6M
Total Assets
$1.3B
$56.4M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RBKB
RBKB
RCEL
RCEL
Q4 25
$18.2M
Q3 25
$23.3M
Q2 25
$15.7M
Q1 25
$25.8M
Q4 24
$35.9M
Q3 24
$44.4M
Q2 24
$54.1M
Q1 24
$68.2M
Stockholders' Equity
RBKB
RBKB
RCEL
RCEL
Q4 25
$136.9M
$-16.6M
Q3 25
$133.0M
$-6.7M
Q2 25
$129.0M
$-12.9M
Q1 25
$126.0M
$-4.6M
Q4 24
$121.8M
$4.5M
Q3 24
$122.7M
$12.2M
Q2 24
$116.2M
$23.9M
Q1 24
$114.3M
$32.6M
Total Assets
RBKB
RBKB
RCEL
RCEL
Q4 25
$1.3B
$56.4M
Q3 25
$1.3B
$63.7M
Q2 25
$1.3B
$58.1M
Q1 25
$1.3B
$69.6M
Q4 24
$1.3B
$79.7M
Q3 24
$1.3B
$81.1M
Q2 24
$1.3B
$87.8M
Q1 24
$1.3B
$97.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RBKB
RBKB
RCEL
RCEL
Operating Cash FlowLast quarter
$11.7M
$-5.4M
Free Cash FlowOCF − Capex
$10.9M
$-6.1M
FCF MarginFCF / Revenue
80.6%
-34.7%
Capex IntensityCapex / Revenue
6.3%
3.8%
Cash ConversionOCF / Net Profit
5.03×
TTM Free Cash FlowTrailing 4 quarters
$19.4M
$-33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RBKB
RBKB
RCEL
RCEL
Q4 25
$11.7M
$-5.4M
Q3 25
$2.2M
$-5.2M
Q2 25
$2.4M
$-10.2M
Q1 25
$4.3M
$-10.3M
Q4 24
$8.5M
$-8.1M
Q3 24
$-3.6M
$-7.2M
Q2 24
$12.0M
$-12.8M
Q1 24
$-3.5M
$-20.9M
Free Cash Flow
RBKB
RBKB
RCEL
RCEL
Q4 25
$10.9M
$-6.1M
Q3 25
$2.0M
$-6.2M
Q2 25
$2.2M
$-10.8M
Q1 25
$4.2M
$-10.5M
Q4 24
$7.7M
$-9.7M
Q3 24
$-3.6M
$-11.0M
Q2 24
$11.8M
$-15.4M
Q1 24
$-3.7M
$-22.0M
FCF Margin
RBKB
RBKB
RCEL
RCEL
Q4 25
80.6%
-34.7%
Q3 25
14.5%
-36.1%
Q2 25
17.2%
-58.4%
Q1 25
32.8%
-56.9%
Q4 24
1023.9%
-52.7%
Q3 24
-469.0%
-56.1%
Q2 24
111.1%
-101.6%
Q1 24
-36.0%
-198.2%
Capex Intensity
RBKB
RBKB
RCEL
RCEL
Q4 25
6.3%
3.8%
Q3 25
1.4%
5.5%
Q2 25
1.4%
2.8%
Q1 25
0.9%
1.2%
Q4 24
105.5%
8.8%
Q3 24
6.3%
19.2%
Q2 24
1.2%
17.5%
Q1 24
2.3%
10.3%
Cash Conversion
RBKB
RBKB
RCEL
RCEL
Q4 25
5.03×
Q3 25
0.83×
Q2 25
0.89×
Q1 25
1.89×
Q4 24
Q3 24
Q2 24
12.27×
Q1 24
-3.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons